https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50571 Wed 28 Feb 2024 15:53:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52589 Wed 28 Feb 2024 15:29:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41157 Wed 15 Feb 2023 10:57:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47144 in vitro. LPS was used to stimulate BEAS-2-B cells, causing the generation of nitric oxide (NO) and other reactive oxygen species (ROS) that had led to cellular apoptosis. The levels of NO and ROS were detected by, Griess reagent kit and dichlorodihydrofluorescein diacetate (DCFH-DA) respectively, whereas, cell apoptosis was studied by Annexin V-FITC and PI staining. The findings revealed that rutin-loaded LCNs significantly reduced NO, ROS levels and prevented apoptosis in BEAS-2B cells. The observations and findings provide a mechanistic understanding of the effectiveness of rutin-loaded LCNs in protecting the bronchial cells against airway inflammation, thus possessing a promising therapeutic option for the management of airway diseases.]]> Wed 14 Dec 2022 15:27:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14155 Wed 11 Apr 2018 16:43:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15981 Wed 11 Apr 2018 14:59:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15695 Wed 11 Apr 2018 12:28:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4301 Wed 11 Apr 2018 10:09:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12423 Wed 11 Apr 2018 09:52:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17958 Wed 11 Apr 2018 09:41:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36818 Wed 08 Jul 2020 11:42:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26567 TM GX Human Inflammation Kit 2. Results: Following the interventions, clinical characteristics and plasma IL-6 and CRP were unchanged. Sputum neutrophil proportion and absolute count was increased and macrophage proportion decreased by rosuvastatin (P = 0.020 and P = 0.015; respectively). Rosuvastatin increased LTB4R and decreased CXCL10 and AGER gene expression in white blood cells. The addition of lycopene and omega-3 fatty acids decreased LTB4R and increased CXCL10 to basal levels, whilst combined use of interventions increased ALOX15 blood gene expression. Conclusion This study shows that rosuvastatin, omega-3 fatty acids and lycopene have some anti-inflammatory effects systemically, but rosuvastatin may increase airway neutrophils, which would be undesirable in COPD patients, warranting further investigation.]]> Wed 02 Mar 2022 14:27:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52880 Tue 31 Oct 2023 10:44:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36521 Tue 26 May 2020 10:11:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21583 Tue 26 Jun 2018 11:28:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31941 Tue 10 Apr 2018 11:22:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34928 Tue 04 Jun 2019 14:03:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26123 Thu 28 Oct 2021 13:04:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27734 Thu 28 Oct 2021 13:04:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:594 99%) was inactivated (and bound to tissue inhibitor of metalloproteinase-1). In neutrophilic asthma, more subjects had NE activity (39%) compared with both healthy control subjects (0%), subjects with eosinophilic asthma (6%), or subjects with paucigranulocytic asthma (0%, p < 0.05). There were strong and consistent positive correlations between interleukin-8, neutrophils, and proteolytic enzymes. MMP-9 was inversely correlated with NE (r = -0.93). Conclusions: Proteolytic enzyme activity in asthma is dependent on the underlying inflammatory phenotype and is differentially regulated with MMP-9 activity a feature of eosinophilic inflammation, and active NE in neutrophilic inflammation.]]> Thu 25 Jul 2013 09:10:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:532 Thu 25 Jul 2013 09:10:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36651 Haemophilus influenzae (NTHi) preparation was demonstrated in the mid-1980s. Subsequently, studies aiming to validate clinical efficacy of this oral treatment were complicated by a number of factors, including the modification of clinical definitions, the implications of which were not recognized at that time. The objective of this review is to integrate our pre-clinical and clinical research in this field conducted over the past 30 years to demonstrate the evolution of the idea of communication between mucosal surfaces through the common mucosal immune system and the development of an effective oral NTHi immunotherapy. Our earliest studies recruited subjects with chronic sputum production and high levels of culture-positive sputum for Gram-negative bacteria but by 2000, the clinical diagnostic focus had switched from "chronic bronchitis" to "chronic obstructive pulmonary disease" (COPD), which was functionally defined using spirometry. This change led to variable clinical trial results, confirming the importance of chronic sputum production and culture-positive sputum. Additional conditioning factors such as patient age and gender were influential in study populations with low culture-positive sputum production. Through this period, studies in human and in rodent models provided new insights into airway protection mechanisms and the pathogenesis of airway inflammation. Key findings were the importance of a dysbiosis within the airway microbiome, and the critical role of an interdependence between the bronchus and the gut, with a Peyer's patch-dependent extra-bronchus "loop" controlling the composition of the bronchus microbiome. Within this context, intercurrent virus infections initiate a microbiome-dependant hypersensitivity reaction involving Peyer's patch-derived Th17 cells. We conclude that whole-cell killed NTHi immunotherapy has consistent and significant benefits when examined in the context of changing clinical disease definitions, age and gender, and has the potential to change the natural history of chronic airway disease.]]> Thu 04 Nov 2021 10:39:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9456 0.05). There was a significant correlation between the greatest percentage fall in forced expiratory volume in 1 s (FEV₁)(r=0.6, P<0.0001), the dose–response slope (r=0.73), cumulative dose (r=0.55) and PD15 (r=0.46) for mannitol and hypertonic saline. The greatest percentage fall in FEV₁to mannitol was less in non-eosinophilic asthma. There was a lower total cell count in mannitol vs. hypertonic-saline-induced sputum. However, sputum eosinophils and neutrophils were not significantly different. Using mannitol, a higher proportion of subjects were classified as having eosinophilic asthma. There were no differences in IL-8, neutrophil elastase or matrix-metalloproteinase 9 concentrations in sputum samples induced with mannitol or hypertonic saline. Conclusion: We conclude that mannitol can be used to induce good-quality sputum, useful for analysis of inflammatory mediators and for predicting the inflammatory phenotype in asthma.]]> Sat 24 Mar 2018 08:41:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1763 Sat 24 Mar 2018 08:27:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10440 106 cfu/mL) was cultured from the sputum of 17 (15%) subjects with stable asthma and was associated with higher total cell counts, proportion and number of neutrophils, sputum IL-8 and 8-isoprostane concentrations. The role of bacteria in potentiating neutrophilic asthma warrants further investigation. Therapies such as antibiotic and antioxidant treatment may be most effective in this sub-group of patients.]]> Sat 24 Mar 2018 08:13:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12329 Sat 24 Mar 2018 08:11:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11169 Sat 24 Mar 2018 08:10:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17925 Sat 24 Mar 2018 07:56:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17886 Sat 24 Mar 2018 07:56:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18365 Sat 24 Mar 2018 07:52:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21544 Sat 24 Mar 2018 07:50:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5604 Sat 24 Mar 2018 07:49:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5638 Sat 24 Mar 2018 07:44:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4804 Sat 24 Mar 2018 07:20:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22049 Sat 24 Mar 2018 07:15:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48673 Mon 27 Mar 2023 14:11:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47496 Mon 23 Jan 2023 11:54:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46232 Mon 14 Nov 2022 12:33:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35650 Mon 13 Nov 2023 11:04:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52682 Fri 20 Oct 2023 09:44:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52668 Fri 20 Oct 2023 09:24:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37335 Fri 19 Feb 2021 16:34:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49776 Fri 02 Jun 2023 17:29:57 AEST ]]>